Skip to main content

Nektar blasts off after eczema drug trial

Submitted by admin on
snippet

Biotech stock Nektar Therapeutics Inc (NASDAQ:NKTR) is soaring today, up 83.7% at $17.52 at last glance, after the company's eczema drug, rezpegaldesleukin, met its primary and secondary goals in a mid-stage study.

Source
Schaeffer's Research

Nektar pads wallet with $90M manufacturing plant sale to Ampersand

Submitted by admin on
snippet

After a protracted rough patch—which has included layoffs, partnership terminations and lawsuits—San Francisco’s Nektar Therapeutics is extending its cash runway with the sale of one of its two main facilities.

Source
Fierce Pharma

Nektar Flags Lilly’s Miscalculations in Rezpeg Atopic Dermatitis Trials

Submitted by admin on
snippet

Nektar Therapeutics on Monday revealed that former partner Eli Lilly had incorrectly calculated efficacy data for its investigational regulatory T-cell stimulator rezpegaldesleukin (rezpeg), which the company is developing as a treatment for atopic dermatitis.

Source
BioSpace

After gathering enough Nektar, Lilly hands back rights to immunology med post-lupus fail

Submitted by admin on
snippet

The writing was on the wall for Nektar Therapeutics and Eli Lilly’s rezpeg collaboration, but, now, the Big Pharma is etching it in permanent marker. Rights for the T regulatory cell stimulator treatment are now headed back to the biotech.

Source
Fierce Biotech

Fresh layoffs at Nektar Therapeutics as it drops lupus program after phase 2 disappointment

Submitted by admin on
snippet

Following a recent phase 2 failure, the San Francisco-based biotech company Nektar Therapeutics has slashed its workforce and axed the development of the protein drug rezpegaldesleukin (Rezpeg) for the treatment of the autoimmune disease systemic lupus erythematosus (SLE).

Source
Biopharma Reporter

After lupus setback, Nektar sticks with immunology but lays off 70% of hometown workforce

Submitted by admin on
snippet

Almost exactly a year after Nektar Therapeutics jettisoned 70% of its staff, the biotech is now contracting again. This time, 60% of its San Francisco-based workforce is being laid off in a reorganization that will also see the C-suite rejigged and a tighter focus on immunology.

Source
Fierce Biotech

Nektar's bitter pill: Phase 2 fail ends Lilly-partnered lupus program and prompts eczema rethink

Submitted by admin on
snippet

Nektar Therapeutics’ hopes of rebuilding its battered business around lupus lie in tatters. The key phase 2 clinical trial of rezpegaldesleukin missed its primary endpoint, prompting partner Eli Lilly to drop plans for further development in lupus and reassess its next steps in atopic dermatitis. 

Source
Fierce Biotech

Catalysts ahead for the smaller players

Submitted by admin on
snippet

Evaluate Vantage has already delved into the key first-quarter clinical data for big pharma and large biotech groups. Now it is the turn of companies with a market cap under $1bn.

Calliditas’s Tarpeyo already has an accelerated approval in IgA nephropathy, but it now needs to make its mark with confirmatory data on a harder endpoint as competition looms. Elsewhere, Madrigal’s hit this week turns attention to other Nash players: both Viking and 89Bio have mid-stage data approaching.

Source
EP Vantage

Nektar and Puretech make strange bedfellows

Submitted by admin on
snippet

If you are wondering what the logic is behind merging an inhaled drug delivery specialist that turned to oncology with a holding company that has a portfolio of disparate healthcare assets you are probably not alone. This morning’s market reaction suggests that investors, too, are puzzled by Nektar’s preliminary approach, confirmed today, to Puretech Health.

Source
EP Vantage